Sunesis sinks on Phase III Qinprezo survival miss
This article was originally published in Scrip
Executive Summary
Sunesis Pharmaceuticals sank 78% to $1.46 per share on 6 October when the company said Qinprezo (vosaroxin) did not meet the Phase III VALOR clinical trial's primary endpoint of a statistically significant improvement in median overall survival compared with placebo.
You may also be interested in...
Stockwatch: The TIGER That Came To Lilly
The reasons behind Lilly's latest clinical failure had much less to do with the indication and more to do with repeating the past mistakes of Inspire and Sunesis. Unfortunately, that same die has already been cast for the trials of Biogen and Ophthotech that are due to report imminently.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.